Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1994 1
2005 1
2008 1
2009 1
2015 2
2017 4
2018 2
2019 2
2020 1
2021 1
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Hoeper MM, et al. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6. N Engl J Med. 2023. PMID: 36877098 Clinical Trial.
The Hodges-Lehmann estimate of the difference between the sotatercept and placebo groups in the change from baseline at week 24 in the 6-minute walk distance was 40.8 m (95% CI, 27.5 to 54.1; P<0.001). The first eight secondary end points were significantly improved wit …
The Hodges-Lehmann estimate of the difference between the sotatercept and placebo groups in the change from baseline at week 24 in the 6-min …
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Neal B, et al. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12. N Engl J Med. 2017. PMID: 28605608 Free article. Clinical Trial.
The rate of the primary outcome was lower with canagliflozin than with placebo (occurring in 26.9 vs. 31.5 participants per 1000 patient-years; hazard ratio, 0.86; 95% confidence interval [CI], 0.75 to 0.97; P<0.001 for noninferiority; P=0.02 for superiority). Al …
The rate of the primary outcome was lower with canagliflozin than with placebo (occurring in 26.9 vs. 31.5 participants per 1000 patient-yea …
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman A, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, Barnes J, Linde PG, de Oliveira Pena J, Badesch DB; PULSAR Trial Investigators. Humbert M, et al. N Engl J Med. 2021 Apr 1;384(13):1204-1215. doi: 10.1056/NEJMoa2024277. N Engl J Med. 2021. PMID: 33789009 Clinical Trial.
The least-squares mean difference between the sotatercept 0.3-mg group and the placebo group in the change from baseline to week 24 in pulmonary vascular resistance was -145.8 dyn . sec . cm(-5) (95% confidence interval [CI], -241.0 to -50.6; P = 0.003). The least-squares …
The least-squares mean difference between the sotatercept 0.3-mg group and the placebo group in the change from baseline to week 24 in pulmo …
A saturated map of common genetic variants associated with human height.
Yengo L, Vedantam S, Marouli E, Sidorenko J, Bartell E, Sakaue S, Graff M, Eliasen AU, Jiang Y, Raghavan S, Miao J, Arias JD, Graham SE, Mukamel RE, Spracklen CN, Yin X, Chen SH, Ferreira T, Highland HH, Ji Y, Karaderi T, Lin K, Lüll K, Malden DE, Medina-Gomez C, Machado M, Moore A, Rüeger S, Sim X, Vrieze S, Ahluwalia TS, Akiyama M, Allison MA, Alvarez M, Andersen MK, Ani A, Appadurai V, Arbeeva L, Bhaskar S, Bielak LF, Bollepalli S, Bonnycastle LL, Bork-Jensen J, Bradfield JP, Bradford Y, Braund PS, Brody JA, Burgdorf KS, Cade BE, Cai H, Cai Q, Campbell A, Cañadas-Garre M, Catamo E, Chai JF, Chai X, Chang LC, Chang YC, Chen CH, Chesi A, Choi SH, Chung RH, Cocca M, Concas MP, Couture C, Cuellar-Partida G, Danning R, Daw EW, Degenhard F, Delgado GE, Delitala A, Demirkan A, Deng X, Devineni P, Dietl A, Dimitriou M, Dimitrov L, Dorajoo R, Ekici AB, Engmann JE, Fairhurst-Hunter Z, Farmaki AE, Faul JD, Fernandez-Lopez JC, Forer L, Francescatto M, Freitag-Wolf S, Fuchsberger C, Galesloot TE, Gao Y, Gao Z, Geller F, Giannakopoulou O, Giulianini F, Gjesing AP, Goel A, Gordon SD, Gorski M, Grove J, Guo X, Gustafsson S, Haessler J, Hansen TF, Havulinna AS, Haworth SJ, He J, Heard-Costa N, … See abstract for full author list ➔ Yengo L, et al. Nature. 2022 Oct;610(7933):704-712. doi: 10.1038/s41586-022-05275-y. Epub 2022 Oct 12. Nature. 2022. PMID: 36224396 Free PMC article.
Calciprotein Particles Induce Endothelial Dysfunction by Impairing Endothelial Nitric Oxide Metabolism.
Feenstra L, Kutikhin AG, Shishkova DK, Buikema H, Zeper LW, Bourgonje AR, Krenning G, Hillebrands JL. Feenstra L, et al. Arterioscler Thromb Vasc Biol. 2023 Mar;43(3):443-455. doi: 10.1161/ATVBAHA.122.318420. Epub 2023 Feb 2. Arterioscler Thromb Vasc Biol. 2023. PMID: 36727521 Free PMC article.
A negative association was observed between NO(x) levels and calcification propensity (r=-0.136; P=0.049) in sera of (early) chronic kidney disease patients. CONCLUSIONS: CPPs cause endothelial cell dysfunction by impairing nitric oxide metabolism and generating oxidative …
A negative association was observed between NO(x) levels and calcification propensity (r=-0.136; P=0.049) in sera of (early) chronic …
Impact of coronary hyperemia on collateral flow correction of coronary microvascular resistance indices.
Boerhout CKM, Veelen AV, Feenstra RGT, de Jong EAM, Namba HF, Beijk MAM, Henriques JP, Piek JJ, van de Hoef TP. Boerhout CKM, et al. Am J Physiol Heart Circ Physiol. 2024 Apr 1;326(4):H1037-H1044. doi: 10.1152/ajpheart.00771.2023. Epub 2024 Feb 23. Am J Physiol Heart Circ Physiol. 2024. PMID: 38391315
From these patients, 24 had hyperemic P(w) measurements available for the evaluation of hyperemic conditions on the derivation of P(w) and its effect on the derivation of both "true" (with measured P(w)) and "estimated" P(w) …
From these patients, 24 had hyperemic P(w) measurements available for the evaluation of hyperemic conditions on the derivation …
Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy.
Kearney K, Brown K, Celermajer DS, Collins N, Cordina R, Corrigan C, Dwyer N, Feenstra J, Keating D, Keogh A, Kotlyar E, Lavender M, McWilliams T, Williams T, Whitford H, Weintraub R, Wrobel J, Ellender C, Anderson J, Lau EM; PHSANZ Registry. Kearney K, et al. Chest. 2024 Apr;165(4):967-977. doi: 10.1016/j.chest.2023.10.037. Epub 2023 Nov 10. Chest. 2024. PMID: 37951349

Patients in the PAH with LHD risk factors group were older (66 13 vs 58 19 years; P < .001), had lower pulmonary vascular resistance (393 266 vs 708 391 dyn.s/cm(5); P = .031), and had worse 6-min walk distance (286 130 vs 327 136 m; P = .005) at diagnosis

…

Patients in the PAH with LHD risk factors group were older (66 13 vs 58 19 years; P < .001), had lower pulmonary vascular resistan

…
Induction of immunoglobulin G Fc receptors by recombinant vaccinia viruses expressing glycoproteins E and I of herpes simplex virus type 1.
Bell S, Cranage M, Borysiewicz L, Minson T. Bell S, et al. J Virol. 1990 May;64(5):2181-6. doi: 10.1128/JVI.64.5.2181-2186.1990. J Virol. 1990. PMID: 2157879 Free PMC article.
C. Johnson and V. Feenstra, J. Virol. 61:2208-2216, 1987; D. C. Johnson, M. C. Frame, M. W. Ligas, A. M. Cross, and N. D. Stow, J. Virol. 62:1347-1354, 1988). ...
C. Johnson and V. Feenstra, J. Virol. 61:2208-2216, 1987; D. C. Johnson, M. C. Frame, M. W. Ligas, A. M. Cross, and N. D. Stow …
Contrast-Enhanced Radiologic Evaluation of Gastric Conduit Emptying After Esophagectomy.
Feenstra ML, Alkemade L, van den Bergh JE, Gisbertz SS, Daams F, van Berge Henegouwen MI, Eshuis WJ. Feenstra ML, et al. Ann Surg Oncol. 2023 Jan;30(1):563-570. doi: 10.1245/s10434-022-12596-9. Epub 2022 Oct 10. Ann Surg Oncol. 2023. PMID: 36210402 Free PMC article.

The median day of NGT removal, initiation of clear liquids, and full liquid and solid intake was 1 to 2 days earlier in the UGI-CE group than in the control group (i.e. POD 4, 4, 5, and 6 vs. POD 5, 5, 6.5, and 8; all p < 0.001). The study found no significant differenc

…
The median day of NGT removal, initiation of clear liquids, and full liquid and solid intake was 1 to 2 days earlier in the UGI-CE group tha …
Dance classes improve self-esteem and quality of life in persons with Parkinson's disease.
Feenstra W, Nonnekes J, Rahimi T, Reinders-Messelink HA, Dijkstra PU, Bloem BR. Feenstra W, et al. J Neurol. 2022 Nov;269(11):5843-5847. doi: 10.1007/s00415-022-11206-8. Epub 2022 Jun 28. J Neurol. 2022. PMID: 35763112 Clinical Trial.
RESULTS: Self-esteem scores were stable across the two baseline measurements and improved significantly after the dance classes (1.5 points improvement between T1b and T2, 95% CI 0.3, 2.7; p = 0.012). Additionally, quality of life as measured with the Parkinson's Disease Q …
RESULTS: Self-esteem scores were stable across the two baseline measurements and improved significantly after the dance classes (1.5 points …
23 results